John F. Crowley, Chairman and CEO of Amicus Therapeutics

Personal Motivation & Diagnosis

• John F. Crowley, Amicus Therapeutics Chairman/CEO, joined biotech in 1998 following the diagnosis of his daughter Megan and son Patrick with Pompe disease, a fatal neuromuscular disorder.
• At the time of diagnosis (March 1998), doctors indicated Megan would likely survive only to age two with no existing treatment.
• Crowley left his role at Bristol Myers Squibb in 2000 after his children required ventilators, driven by a need to accelerate the development of life-extending therapies.
• He co-founded Novozyme Therapeutics (later Amicus) to develop enzyme replacement therapy (ERT) with a focus on carbohydrate manipulation for better muscle uptake.

Clinical Progress & ATGAA (Pompe Disease)

• Amicus has completed pivotal Phase 3 studies for ATGAA (atogepan, likely a specific ERT candidate for Pompe, though transcript implies enzyme therapy) and announced a successful pre-Pre-BLA meeting with the FDA.
• FDA feedback was aligned with Amicus's submission plan, providing a path toward approval.
• Clinical data indicates that switching patients from standard of care to Amicus's therapy results in increased strength and improved function for nearly every patient.
• Specific patient benefits observed include:
  • Enhanced ability to walk further for ambulatory patients.
  • Improved breathing capacity for non-ventilated patients.
  • For ventilated patients like Megan Crowley, improvements in arm mobility and the ability to speak more clearly.
• Patient-centric goals identified in early studies included breathing without a ventilator for one minute and improving speech for college socialization.

Corporate Strategy & Product Portfolio

• Amicus' original technology led to the approval of Fabrazyme (referred to as "Febre" in transcript, likely Fabrazyme for Fabry disease), a highly successful product for a different rare disease.
• The company shifted Pompe strategy in 2010 after a previous clinical program failed, transitioning to a new enzyme therapy approach developed by Chief Science Officer Hung Do.
• The new approach focused on better targeting of the enzyme and improved manufacturability, taking six years to move from concept to clinic.
• Amicus is currently preparing for a global launch to increase patient choice and access to medicine.

Leadership & Crisis Management (COVID-19)

• During the pandemic, Amicus implemented "Amicus Cares," including a one-time $1,000 bonus for all non-executive employees to provide financial stability and demonstrate care.
• Leadership adopted a "visible leader" protocol, holding small Zoom sessions within 30 days to meet every employee individually.
• Crowley highlighted the biopharma ecosystem's ability to accelerate development, noting the shift from a predicted 3-7 year vaccine timeline to actual development in months through collaboration with the FDA and manufacturing partners.
• Key lessons from the pandemic include the necessity of beating time, maintaining regulatory gold standards, and ensuring 100% patient access.

Military Experience & Leadership Philosophy

• Crowley is a U.S. Naval officer and veteran of the Joint Special Operations Command (JSOC), including a rotation in Afghanistan.
• He cites military service as instilling core principles of servant leadership, integrity, and the understanding that work is "bigger than you."
• A defining experience involved the loss of 31 teammates (Navy SEALs) in a helicopter incident shortly after Crowley departed the unit, reinforcing the cost of sacrifice and the importance of purpose.
• He applies military crisis management principles to Amicus, emphasizing transparency, measured confidence, and rapid decision-making during uncertainty.

Patient Legacy & Personal Reflections

• Megan Crowley, now 24 and a graduate of the University of Notre Dame, is pursuing a master's in social work at the University of North Carolina with the goal of helping children with rare diseases.
• Her experience highlights the resiliency of Pompe patients, including her ability to graduate on time despite physical limitations requiring double or triple the time for daily tasks.
• Crowley notes that his children have taught him more about love, living, and purpose than he taught them.

Forward-Looking Statements

• Amicus aims to become a leading global biotech company by expanding its portfolio beyond Fabry and Pompe diseases.
• The company views the successful FDA interaction for ATGAA as a critical step toward launching a new therapy that improves quality of life for a significantly underserved population.
• Crowley believes the biotech sector can replicate the speed and collaboration seen during the pandemic to accelerate rare disease treatments in the future.